Association of low muscle mass and obesity with mortality and cardiovascular outcomes in breast cancer: a population-based study.
1/5 보강
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 44.0%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[PURPOSE] Obesity and low muscle mass (LMM) have been associated with adverse outcomes in cancer population.
- 95% CI 1.15-1.40
- 추적기간 4.63 years
APA
Chun S, Lee HR, et al. (2026). Association of low muscle mass and obesity with mortality and cardiovascular outcomes in breast cancer: a population-based study.. Breast cancer research and treatment, 215(3), 70. https://doi.org/10.1007/s10549-026-07899-4
MLA
Chun S, et al.. "Association of low muscle mass and obesity with mortality and cardiovascular outcomes in breast cancer: a population-based study.." Breast cancer research and treatment, vol. 215, no. 3, 2026, pp. 70.
PMID
41636872 ↗
Abstract 한글 요약
[PURPOSE] Obesity and low muscle mass (LMM) have been associated with adverse outcomes in cancer population. However, their individual and combined effects on long-term mortality and cardiovascular disease (CVD) outcomes in breast cancer patients are not well characterized.
[METHODS] We conducted a retrospective study of 46,037 women aged 40 years and older with pathologically confirmed breast adenocarcinoma using data from the Cancer Public Library Database. LMM was defined as the lowest quartile of appendicular skeletal muscle mass index (ASMI), estimated by a validated equation. The remaining quartiles were classified as normal muscle mass (NMM). Obesity was defined as BMI ≥ 25 kg/m. Patients were categorized into four groups by muscle mass and obesity status. Multivariable Cox proportional hazards models assessed associations with overall, cancer-specific, and cardiovascular mortality, and incident CVD.
[RESULTS] Over a mean follow-up of 4.63 years, 2,286 deaths and 851 incident CVD events were recorded. Compared to NMM, LMM was independently associated with increased overall (adjusted hazard ratio [aHR] 1.27, 95% CI 1.15-1.40), cancer-specific (aHR 1.19, 95% CI 1.08-1.32), and cardiovascular (aHR 1.76, 95% CI 1.10-2.81) mortality. When stratified by muscle-obesity status, the LMM with obesity group had the highest risk of overall (aHR 1.69, 95% CI 1.18-2.42) and cancer (aHR 1.58, 95% CI 1.03-2.43) mortality. LMM without obesity was also associated with increased overall, cancer, and cardiovascular mortality.
[CONCLUSIONS] LMM was independently associated with increased mortality in breast cancer patients, with risk amplified in those with coexisting obesity.
[METHODS] We conducted a retrospective study of 46,037 women aged 40 years and older with pathologically confirmed breast adenocarcinoma using data from the Cancer Public Library Database. LMM was defined as the lowest quartile of appendicular skeletal muscle mass index (ASMI), estimated by a validated equation. The remaining quartiles were classified as normal muscle mass (NMM). Obesity was defined as BMI ≥ 25 kg/m. Patients were categorized into four groups by muscle mass and obesity status. Multivariable Cox proportional hazards models assessed associations with overall, cancer-specific, and cardiovascular mortality, and incident CVD.
[RESULTS] Over a mean follow-up of 4.63 years, 2,286 deaths and 851 incident CVD events were recorded. Compared to NMM, LMM was independently associated with increased overall (adjusted hazard ratio [aHR] 1.27, 95% CI 1.15-1.40), cancer-specific (aHR 1.19, 95% CI 1.08-1.32), and cardiovascular (aHR 1.76, 95% CI 1.10-2.81) mortality. When stratified by muscle-obesity status, the LMM with obesity group had the highest risk of overall (aHR 1.69, 95% CI 1.18-2.42) and cancer (aHR 1.58, 95% CI 1.03-2.43) mortality. LMM without obesity was also associated with increased overall, cancer, and cardiovascular mortality.
[CONCLUSIONS] LMM was independently associated with increased mortality in breast cancer patients, with risk amplified in those with coexisting obesity.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.